SCHEMBL3223835

SCHEMBL3223835

O=C(O)[C@H]1C[C@H]2CCC[C@@H](C1)C2=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 2/20 0.47
USP2 O75604 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
ALDH1A1 P00352 3/20 0.44
AKR1C3 P42330 1/20 0.42
AKR1C1 Q04828 1/20 0.42
GAA P10253 2/20 0.41
MAPK1 P28482 1/20 0.39
POLB P06746 1/20 0.35
TSHR P16473 2/20 0.34
GABRP O00591 1/20 0.34
GABRD O14764 1/20 0.34
GABRA1 P14867 1/20 0.34
GABRB1 P18505 1/20 0.34
GABRG2 P18507 1/20 0.34
GABRB3 P28472 1/20 0.34
GABRA5 P31644 1/20 0.34
GABRA3 P34903 1/20 0.34
GABRA2 P47869 1/20 0.34
GABRB2 P47870 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3212635 1.00 ALOX15 (0.47) ALOX15USP2SMN1; SMN2ALDH1A1AKR1C3
SCHEMBL3212637 1.00 ALOX15 (0.47) ALOX15USP2SMN1; SMN2ALDH1A1AKR1C3
SCHEMBL4983462 0.91 AKR1C3 (0.50) ALOX15USP2SMN1; SMN2ALDH1A1AKR1C3
SCHEMBL3212513 0.91 AKR1C3 (0.50) ALOX15USP2SMN1; SMN2ALDH1A1AKR1C3
SCHEMBL3212519 0.91 AKR1C3 (0.50) ALOX15USP2SMN1; SMN2ALDH1A1AKR1C3
SCHEMBL17207722 0.77 AKR1C3 (0.38) ALOX15USP2SMN1; SMN2AKR1C3AKR1C1
SCHEMBL21695107 0.77
SCHEMBL1557264 0.76 AKR1C3 (0.37) ALOX15USP2ALDH1A1AKR1C3AKR1C1
SCHEMBL328849 0.75 ALDH1A1 (0.47) ALOX15USP2SMN1; SMN2ALDH1A1GAA
SCHEMBL3225044 0.74 ALDH1A1 (0.42) ALOX15USP2SMN1; SMN2ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8710077-B2 Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives SANOFI (FR) 2014-04-29 US disclosed
EP-2102164-B1 CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES SANOFI AVENTIS (FR) 2010-12-01 EP disclosed
US-20100056553-A1 Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives SANOFI-AVENTIS (FR) 2010-03-04 US disclosed
EP-2102164-A1 CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES Sanofi-Aventis (FR) 2009-09-23 EP disclosed
WO-2008077556-A1 CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES SANOFI-AVENTIS (FR) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056553-A1 Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives MYLK2, MYLK, MYLK3 ALOX15 3954/4885USP2 3261/4885SMN1; SMN2 1471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.